{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:19:36Z","timestamp":1793215176123,"version":"4.5.0"},"reference-count":20,"publisher":"FapUNIFESP (SciELO)","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Assoc. Med. Bras."],"abstract":"<jats:p>SUMMARY  BACKGROUND: The prognostic value of TP53 mutations in metastatic colorectal cancer remains unclear owing to inconsistent findings in the literature. Given its central role in tumor biology, clarifying the impact of TP53 status on survival outcomes is clinically relevant.  METHODS: This retrospective cohort study included 115 patients with metastatic colorectal cancer who underwent TP53 mutational analysis using next-generation sequencing (KAPA HyperPETE Pan Cancer Panel). Eligible patients were aged \u226518 years, had histologically confirmed metastatic colorectal cancer, and received first-line systemic therapy. Patients with incomplete clinical or molecular data were excluded. Based on mutation profiles, those with RAS or BRAF mutations received anti-VEGF therapy, whereas patients with wild-type tumors received anti-EGFR treatment. Patients were stratified according to TP53 mutation status to evaluate differences in clinical outcomes.  RESULTS: Among the 115 patients included, 78 (67.8%) harbored TP53 mutations and 37 (32.2%) had wild-type TP53. The median progression-free survival was significantly longer in the TP53-mutant group (18.6 vs. 10.0 months; p=0.002). The median overall survival was also numerically longer in the TP53-mutant group (32.9 vs. 30.3 months), although this difference was not statistically significant (p=0.114). In the univariate analysis, TP53 mutation was associated with improved progression-free survival (HR 0.479; 95%CI 0.294\u20130.779; p=0.003). This association remained independently significant in the multivariate analysis (HR 0.477; 95%CI 0.289\u20130.787; p=0.004). None of the other variables consistently predicted survival.  CONCLUSION: TP53 mutations appear to be an independent prognostic marker for prolonged progression-free survival in patients with metastatic colorectal cancer. Although the difference in overall survival was not statistically significant, these findings warrant further validation in prospective studies to confirm the prognostic utility of TP53 in therapeutic stratification.<\/jats:p>","DOI":"10.1590\/1806-9282.20250998","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T13:09:27Z","timestamp":1774876167000},"source":"Crossref","is-referenced-by-count":1,"title":["Clinical impact of TP53 mutation status on survival outcomes in metastatic colorectal cancer"],"prefix":"10.1590","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4057-3108","authenticated-orcid":false,"given":"O\u011fuzhan","family":"Y\u0131ld\u0131z","sequence":"first","affiliation":[{"name":"Necmettin Erbakan University,  T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7809-1721","authenticated-orcid":false,"given":"Hakan \u015eat","family":"Bozcuk","sequence":"additional","affiliation":[{"name":"Medical Park Antalya Hospital,  T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2597-5931","authenticated-orcid":false,"given":"Melek Karakurt","family":"Ery\u0131lmaz","sequence":"additional","affiliation":[{"name":"Necmettin Erbakan University,  T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4632-9501","authenticated-orcid":false,"given":"Murat","family":"Araz","sequence":"additional","affiliation":[{"name":"Necmettin Erbakan University,  T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1455-471X","authenticated-orcid":false,"given":"Ali Fuat","family":"G\u00fcrb\u00fcz","sequence":"additional","affiliation":[{"name":"Necmettin Erbakan University,  T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3986-5517","authenticated-orcid":false,"given":"Mahmut Selman","family":"Y\u0131ld\u0131r\u0131m","sequence":"additional","affiliation":[{"name":"Necmettin Erbakan University,  T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2335-3354","authenticated-orcid":false,"given":"Mehmet","family":"Arta\u00e7","sequence":"additional","affiliation":[{"name":"Necmettin Erbakan University,  T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","published-online":{"date-parts":[[2026]]},"reference":[{"issue":"7","key":"ref1","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/jama.2021.0106","article-title":"Diagnosis and treatment of metastatic colorectal cancer: a review.","volume":"325","author":"Biller LH","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"ref2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41392-020-0116-z","article-title":"Comprehensive review of targeted therapy for colorectal cancer.","volume":"5","author":"Xie YH","year":"2020","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-023-01347-1","article-title":"Targeting p53 pathways: mechanisms, structures, and advances in therapy.","volume":"8","author":"Wang H","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"1d","key":"ref4","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4314\/dujopas.v11i1d.31","article-title":"Understanding colorectal cancer: risk factors, molecular subtypes, and therapeutic approaches.","volume":"11","author":"Kabir IM","year":"2025","journal-title":"Dutse J Pure Appl Sci"},{"issue":"8","key":"ref5","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41568-020-0262-1","article-title":"p53: 800 million years of evolution and 40 years of discovery.","volume":"20","author":"Levine AJ","year":"2020","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"ref6","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41418-018-0246-9","article-title":"Mutant p53 as a guardian of the cancer cell.","volume":"26","author":"Mantovani F","year":"2019","journal-title":"Cell Death Differ"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1016\/j.csbj.2024.11.037","article-title":"Deep learning algorithm on H&E whole slide images to characterize TP53 alterations frequency and spatial distribution in breast cancer.","volume":"23","author":"Frascarelli C","year":"2024","journal-title":"Comput Struct Biotechnol J"},{"issue":"3","key":"ref8","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/humu.10175","article-title":"TP53 mutation in colorectal cancer.","volume":"21","author":"Iacopetta B","year":"2003","journal-title":"Hum Mutat"},{"issue":"21","key":"ref9","doi-asserted-by":"crossref","first-page":"5394","DOI":"10.3390\/cancers13215394","article-title":"APC and TP53 mutations predict cetuximab sensitivity across consensus molecular subtypes.","volume":"13","author":"Thota R","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"17","key":"ref10","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.3390\/cancers16173069","article-title":"TP53 mutation-mediated immune evasion in cancer: mechanisms and therapeutic implications.","volume":"16","author":"Wang C","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"4","key":"ref11","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/14737159.2019.1592679","article-title":"Advances in prognostic markers for colorectal cancer.","volume":"19","author":"Duan L","year":"2019","journal-title":"Expert Rev Mol Diagn"},{"issue":"5","key":"ref12","doi-asserted-by":"crossref","first-page":"705","DOI":"10.18632\/oncotarget.974","article-title":"P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy.","volume":"4","author":"Said R","year":"2013","journal-title":"Oncotarget"},{"issue":"5","key":"ref13","doi-asserted-by":"crossref","first-page":"1010428317703651","DOI":"10.1177\/1010428317703651","article-title":"The prognostic value of p53 positive in colorectal cancer: a retrospective cohort study.","volume":"39","author":"Wang P","year":"2017","journal-title":"Tumour Biol"},{"issue":"9","key":"ref14","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/sj.bjc.6602358","article-title":"P53 abnormalities and outcomes in colorectal cancer: a systematic review.","volume":"92","author":"Munro AJ","year":"2005","journal-title":"Br J Cancer"},{"issue":"1","key":"ref15","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1186\/s12885-022-10039-y","article-title":"Clinical significance of p53 protein expression and TP53 variation status in colorectal cancer.","volume":"22","author":"Kim KM","year":"2022","journal-title":"BMC Cancer"},{"issue":"1","key":"ref16","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1186\/s12885-024-12776-8","article-title":"Combined KRAS and TP53 mutation in patients with colorectal cancer enhance chemoresistance to promote postoperative recurrence and metastasis.","volume":"24","author":"Tang Y","year":"2024","journal-title":"BMC Cancer"},{"issue":"4","key":"ref17","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1245\/s10434-024-16822-4","article-title":"Associations of KRAS point mutations with survival of patients who underwent curative-intent resection of colorectal liver metastases.","volume":"32","author":"Maki H","year":"2025","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"ref18","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1002\/ijc.34347","article-title":"Timevarying prognostic value of primary tumor sidedness in metastatic colorectal cancer: a population-based study and meta-analysis.","volume":"152","author":"Kruijssen DEW","year":"2023","journal-title":"Int J Cancer"},{"issue":"3","key":"ref19","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1007\/s12029-020-00514-9","article-title":"The real-life data of BRAF mutation on the treatment of colorectal cancer: a TOG study.","volume":"52","author":"Beypinar I","year":"2021","journal-title":"J Gastrointest Cancer"},{"issue":"6","key":"ref20","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.ccell.2024.04.009","article-title":"Understanding the complexity of p53 in a new era of tumor suppression.","volume":"42","author":"Liu Y","year":"2024","journal-title":"Cancer Cell"}],"container-title":["Revista da Associa\u00e7\u00e3o M\u00e9dica Brasileira"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_pdf&pid=S0104-42302026000102217&tlng=en","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T13:09:29Z","timestamp":1774876169000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0104-42302026000102217&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026]]}},"alternative-id":["S0104-42302026000102217"],"URL":"https:\/\/doi.org\/10.1590\/1806-9282.20250998","relation":{},"ISSN":["1806-9282","0104-4230"],"issn-type":[{"value":"1806-9282","type":"electronic"},{"value":"0104-4230","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"e20250998"}}